NovaBridge Biosciences
givastomig
HER2-negative metastatic gastric cancer
Date
TBD
FDA decision · Date TBD estimated
What's at stake
The FDA's approval decision on givastomig for HER2-negative metastatic gastric cancer is due Date TBD. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 15h ago
“the FDA has set a PDUFA action date of March 27, 2026”